$MRSH

South Martin sold $1.3M of MRSH

South Martin (Chief Client Officer) sold 7,100 shares of MARSH & MCLENNAN COMPANIES, INC. (MRSH) at $189.99 ($1.35M total) on 2026-07-28.

Original reporting
SEC EDGAR · South Martin
Published Jul 29, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MRSH
Neutral
high confidence
Mentioned
$MRSH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MRSHNeutralLow
01

Why it matters

The newest fact is the reported open-market sale size, price, and post-transaction holdings by the Chief Client Officer.

02

Market read

Traders may note insider selling, but the disclosure alone does not provide a new fundamental catalyst.

03

What to watch

The article notes no 10b5-1 plan; however, it still lacks context on motivations, compensation timing, or whether other insiders are buying.

Relevance 6/10Novelty 3/10Timing: Filed 2026-07-29, covering a sale executed 2026-07-28.

Background

The article is a SEC Form 4 insider transaction disclosure for Marsh & McLennan (MRSH).

Company-level read

Ticker impact

$MRSHNeutralHigh confidence
Context

Marsh & McLennan insider South Martin sold 7,100 shares on 2026-07-28 at $189.9925, totaling about $1.35M.

Expected impact

Likely minimal near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is an insider sale (not a buy), and the text provides no accompanying company-specific catalyst such as guidance, contracts, or litigation.

Market effects

No clear sector read-through from a single insider sale disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so the signal may be overstated.

Key entities

  • Marsh & McLennan Companies, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • South Martin

    Chief Client Officer who sold shares via open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BROMedAI 8/10

Winners And Losers Of Q2: Baldwin Insurance Group (NASDAQ:BWIN) Vs The Rest Of The Insurance Brokers Stocks

Ryan Specialty beat estimates but fell 11.1% to $39.20. Brown & Brown (BRO) reported $1.68B revenue, up 30.4% YoY, missing estimates by 2.5%, and dropped 3.4% to $67.32. Arthur J. Gallagher (AJG) reported $4.00B revenue, up 24.3% YoY, missing estimates by 0.5%, and fell 3.3% to $248.05. Marsh (MRSH) reported $7.40B revenue, up 6.2% YoY, beating estimates by 1.8%, and dropped 1.2% to $179.91.

MedAI 8/10

Marsh McLennan Agency to acquire century-old Iowa broker Accel Group

Marsh McLennan Agency (MMA) will acquire Accel Group, a privately held Iowa-based insurance broker founded in 1936, with seven offices and 130+ employees. Accel’s services include commercial and personal insurance, employee benefits, agribusiness coverage, and wealth and retirement advisory. MMA said the deal expands rural and agribusiness capacity, following similar regional acquisitions.

$MRSHMed

Marsh & McLennan Companies Q2 Earnings Call Highlights

Marsh & McLennan (NYSE:MRSH) reported Q2 results and discussed market conditions on its earnings call. Consulting revenue rose 10% to $2.6B, with adjusted operating income up 11% to $533M. Mercer revenue was $1.6B. Marsh Global Insurance Market Index showed primary commercial rates down 6% in Q2. The company ended with $20.6B debt and $1.7B cash, and expects $5.5B capital deployment in 2026.

$MRSHMed

Marsh (NYSE:MRSH) Exceeds Q2 CY2026 Expectations

Marsh (NYSE:MRSH) reported Q2 CY2026 results. Revenue rose 6.2% year on year to $7.40 billion, exceeding Wall Street’s estimate by 1.8%, and non-GAAP EPS was $2.96, 2.3% above consensus. Adjusted operating margin was 26.9%. Analysts expect revenue growth of 4.2% and full-year EPS to rise from $10.22 to $10.90.